Abstract
Fifty patients with breast cancer refractory to endocrine manipulation and/or combination chemotherapy were treated with mitomycin‐C 20 mg/m2 I.V. every 4–6 weeks and megestrol acetate 160 mg daily. Of 48 evaluable patients, 4% achieved complete remission (CR), 23% had partial remission (PR). Median duration of response for CR and PR was 7 months. Non‐responders had a median survival of 2 months. The difference in survival of responders (both CR and PR) and non‐responders was statistically significant at p<0.01 level. Attenuated doses of mitomycin‐C were administered at increasing intervals due to cumulative myelosuppressive toxicity.
Original language | English (US) |
---|---|
Pages (from-to) | 392-395 |
Number of pages | 4 |
Journal | Cancer |
Volume | 41 |
Issue number | 2 |
DOIs | |
State | Published - Feb 1978 |
Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research